Literature DB >> 33580969

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.

Fortunato Morabito1,2, Giovanni Tripepi3, Giovanni Del Poeta4, Francesca Romana Mauro5, Gianluigi Reda6, Paolo Sportoletti7, Luca Laurenti8, Marta Coscia9, Yair Herishanu10, Marzia Varettoni11, Roberta Murru12, Annalisa Chiarenza13, Andrea Visentin14, Adalgisa Condoluci15, Riccardo Moia16, Daniela Pietrasanta17, Giacomo Loseto18, Ugo Consoli19, Ilaria Scortechini20, Francesca Maria Rossi21, Antonella Zucchetto21, Ernesto Vigna1,22, Enrica Antonia Martino22, Francesco Mendicino22, Cirino Botta22, Daniele Caracciolo22, Ramona Cassin6, Graziella D'Arrigo3, Sara Galimberti23, Angela Rago24, Ilaria Angeletti25, Annalisa Biagi4, Ilaria Del Giudice5, Riccardo Bomben21, Antonino Neri6, Gilberto Fronza26, Giovanna Cutrona27, Davide Rossi15, Francesco Di Raimondo13, Antonio Cuneo28, Gianluca Gaidano16, Aaron Polliack29, Livio Trentin14, Robin Foà5, Manlio Ferrarini30, Valter Gattei21, Massimo Gentile1,22.   

Abstract

Entities:  

Year:  2021        PMID: 33580969     DOI: 10.1002/ajh.26127

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.

北京卡尤迪生物科技股份有限公司 © 2022-2023.